Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase II single-arm study of anlotinib in relapsed or refractory peripheral T-cell lymphoma
ChiCTR2000033939Phase 2Recruiting
- Sponsor
- Affiliated Cancer Hospital of Nanjing Medical University
- Start
- Jun 2020
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of anlotinib in peripheral T-cell lymphoma (PTCL), sponsored by Affiliated Cancer Hospital of Nanjing Medical University. Primary endpoint: Objective response rate. Started Jun 2020; status: recruiting.
02
Drugs
anlotinib
03
Conditions
peripheral T-cell lymphoma (PTCL)
Beyond the preview
Go deeper on ChiCTR2000033939.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR2000033939.